-transparent.png){kind=logo}
KF22678, a novel thioester derivative of leinamycin with the 1-oxo-1,2-dithiolane-3-one moiety, was examined for anti-tumor activity, toxicity in mice and activation mechanism. KF22678 showed a broad antitumor spectrum against human carcinoma xenografts (lung, colon, ovary and prostate). The efficacy of KF22678 was significantly higher than that of cisplatin. KF22678 exhibited low cross-resistance against various drug-resistant cell lines of MDR1 or MRP overexpressing human tumors, and, in addition, exhibited more potent antitumor activity in vivo than ADM against A2780/ADM and KB/MRP xenograft. DL-Buthionine sulfoximine (BSO) pretreatment significantly reduced intracellular glutathione (GSH) level in human lung carcinoma A549 cells, leading to decrease in the cytotoxicity of KF22678, whereas the cytotoxicity of melphalan was augmented by BSO pretreatment. DNA single-strand breaks (SSB) were observed in A549 cells treated with KF22678 and bleomycin. DNA SSB induced by KF22678 was greatly reduced in the presence of BSO in the cells, whereas DNA SSB induced by bleomycin was not. In addition, the antitumor activity of KF22678 against BSO-pretreated human lung carcinoma PC-9 tumor was significantly decreased. These results suggest that the activation of KF22678 by intracellular GSH might be important for DNA SSB and antitumor activity in vitro and in vivo.
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
April 1999,
Journal of medicinal chemistry,
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
August 1999,
Drug discovery today,
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
June 1990,
Biochemistry,
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
March 1998,
Anti-cancer drugs,
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
January 1991,
Cancer chemotherapy and pharmacology,
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
March 1997,
Japanese journal of cancer research : Gann,
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
May 1985,
Cancer treatment reports,
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
May 2021,
Molecules (Basel, Switzerland),
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
October 1997,
Anti-cancer drugs,
T Ashizawa, and
K Kawashima, and
Y Kanda, and
K Gomi, and
M Okabe, and
K Ueda, and
T Tamaoki
May 2004,
Toxicology letters,
